Zobrazeno 1 - 10
of 76
pro vyhledávání: '"SAMUEL VOKURKA"'
Autor:
P Kouřilová, D Navrátilová-Hrabánková, M Novosadová, M Labudíková, V Jánská, E Faber, J Cvek, K Jirsová, Simona Šípová, L Pochop, P Holečková, Samuel Vokurka, Šárka Kozáková, J Liška
Publikováno v:
Klinicka onkologie.
BACKGROUND Oral cavity injuries are very significant complications in the treatment of oncological and hemato-oncological patients. Preventive and curative interventions and patient education reduce the risk of complications and their consequences. A
Publikováno v:
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti. 33(6)
Stomatitis associated with targeted oncological therapy, typically everolimus related one, belongs among the major complications affecting the quality of life of a patient and intensity of his/her oncological treatment. Corticosteroids, especially fo
Publikováno v:
Klinicka Onkologie. 33
BACKGROUND Stomatitis associated with targeted oncological therapy, typically everolimus related one, belongs among the major complications affecting the quality of life of a patient and intensity of his/her oncological treatment. Corticosteroids, es
Autor:
Samuel, Vokurka, Viktor, Maňásek, Darja, Hrabánková Navrátilová, Simona, Šípová, Zuzana, Šustková, Lenka, Turková, Erika, Fukasová Hajnová, Zuzana, Sýkorová, Šárka, Kozáková, Jitka, Wintnerová
Publikováno v:
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti. 33(5)
Extravasation (paravasation) of chemotherapy drugs is a very significant complication. Preventive and therapeutic interventions reduce the risk of the complication or the extent of its consequences. A working group of authors from expert groups prepa
Autor:
Simona Šípová, E Hajnová Fukasová, Lenka Turková, Šárka Kozáková, D Navrátilová Hrabánková, Viktor Maňásek, R Mazúr, Samuel Vokurka, Jitka Wintnerova, Zuzana Sýkorová
Publikováno v:
Klinicka Onkologie. 32
Background Extravasation (paravasation) of chemotherapy drugs is a very significant complication in the treatment of cancer patients. Preventive and therapeutic interventions reduce the risk of this complication or the extent of its consequences. A w
Publikováno v:
Anticancer Research. 38:4149-4152
BACKGROUND/AIM To verify perfusion differences in white matter adjacent to glioblastomas and metastatic tumors in dynamic contrast-enhanced (DCE) 3T-magnetic resonance imaging (MRI) using gradient echo (GRE) T1 techniques. MATERIALS AND METHODS A ret
Autor:
Andrea Janíková, Michaela Hamouzova, Marek Trneny, Samuel Vokurka, Jiri Mayer, Jan Pirnos, Heidi Mocikova, Natasa Kopalova, Vít Procházka, Zbynek Bortlicek, Robert Pytlik, Vit Campr, Juraj Duras, Katerina Benesova, David Belada
Publikováno v:
Annals of Hematology. 97:669-678
The aim of this study is to assess the incidence, risk factors, and outcome of biopsy-proven transformation in follicular lymphoma (FL) patients in the rituximab era. Transformation was analyzed in 1233 patients with initially diagnosed FL grades 1
Publikováno v:
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti. 32(5)
Damage and loss of hair (alopecia) is a predictable adverse event of oncological therapy. It can be caused by chemotherapy, radiotherapy, or targeted and hormonal therapy. From the point of view of patients with malignant disease, hair loss is one of
Autor:
Šárka Kozáková, Simona Šípová, Viktor Manasek, Zuzana Sykorova, Jitka Wintnerova, Erika Hajnova Fukasova, Lenka Turková, Samuel Vokurka, Darja Navratilova Hrabankova, Zuzana Sustkova
Publikováno v:
Journal of Nursing Education and Practice. 10:76
Extravasation (paravasation) of cytotoxic chemotherapy drugs represents a very important complication in oncology nursing. Prevention and proper care can reduce the risk of extravasation and its consequences. A consensus on chemotherapy extravasation
Autor:
Ľuboš Drgoňa, Zdeněk Král, Miriam Ladická, Marie Lukasova, Vít Procházka, Andrej Vranovský, David Belada, Heidi Mocikova, Roman Hájek, Veronika Ballová, Juraj Ďuraš, Samuel Vokurka, Jozef Michalka, Jana Markova, Alexandra Jungova, Ladislav Dušek, Alice Sýkorová
Publikováno v:
Journal of Cancer
Introduction: Clinical trials have demonstrated the effectiveness of the CD30-targeted antibody-drug conjugate brentuximab vedotin (BV) for the treatment of relapsed/refractory Hodgkin lymphoma (R/R HL). In this study, we report on outcomes with BV i